Brief: Abbisko Cayman Says Abbisko Therapeutics Receives $85Mn From Merck
29/05/2025 09:17
May 29 (Reuters) - Abbisko Cayman Ltd 2256.HK: ABBISKO THERAPEUTICS RECEIVES US$85MN FROM- MERCK IN CONSIDERATION FOR PIMICOTINIB (ABSK021) GLOBAL- COMMERCIALIZATION OPTION Further company coverage: 2256.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abbisko Cayman
See all newsHK-listed Abbisko climbs most in 12 weeks on Eli Lilly tie-up
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly (updated)
Brief: Abbisko Therapeutics Deepens R+D- Collaboration With Lilly
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly
Brief: Abbisko Therapeutics Enters Strategic Research Collaboration And License Agreement With Eli Lilly